CAR-37 T Cells for Blood Cancers

Recruiting in Palo Alto (17 mi)

Overseen by Matthew J. Frigault, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Marcela V. Maus, M.D.,Ph.D.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the side effects when treated with CAR-37 T Cells. - Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) is an investigational treatment

Research Team

Matthew J. Frigault, MD

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

This trial is for adults over 18 with certain blood cancers like B-cell lymphoma, leukemia, and T-cell lymphoma that have come back or didn't respond to treatment. They must be in decent physical shape (ECOG 0-2), have tried specific previous treatments including anti-CD20 therapy and possibly a BTK inhibitor, and not be pregnant or breastfeeding. People can't join if they've had recent heart problems, other cancer treatments within the last week (except low-dose steroids), or active infections.

Inclusion Criteria

I am currently on or have been treated with BTK inhibitor therapy.

I am 18 years old or older.

My cancer has returned or didn't respond to treatment and tests positive for CD37.

Exclusion Criteria

I have not received treatments targeting CD37 before.

I am currently on long-term immune system suppressing drugs.

I do not have any ongoing serious infections.

Treatment Details

Interventions

• CAR-37 T Cells (CAR T-cell Therapy)

Trial Overview The study tests CAR-37 T Cells as an experimental therapy for patients with CD37+ hematologic malignancies that are relapsed/refractory. It aims to evaluate the effectiveness of this treatment and understand its side effects.

Participant Groups

Group I: CAR-37 T cells Dose Escalation Experimental Treatment 1 Intervention

* CAR-37 will be administered intravenously on day 0 * Enrolled subjects will undergo a leukapheresis procedure processing approximately two times the subject's total blood volume. * CAR-37 will undergo dose escalation

Group II: CAR-37 T cells Experimental Treatment 1 Intervention

* CAR-37 will be administered intravenously on day 0 * Enrolled subjects will undergo a leukapheresis procedure processing approximately two times the subject's total blood volume. * Subjects will receive 3 days of lymphodepleting chemotherapy starting Day -5, before the infusion of CAR-37 T cells on Day 0

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Massachusetts General Hospital Cancer Center Boston, MA

Who Is Running the Clinical Trial?

Marcela V. Maus, M.D.,Ph.D.

Lead Sponsor

Trials

6

Patients Recruited

110+

References